title: Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
abstract: Atorvastatin and rosuvastatin at maximal doses are both highly effective in lowering low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels. Rosuvastatin has been shown to be more effective than atorvastatin in lowering LDL-C, small dense LDL-C and in raising high-density lipoprotein (HDL) and its subclasses. Intestinal lipoproteins containing apolipoprotein (apo) B-48 are also thought to be atherogenic particles. Our purpose in this study was to compare the effects of daily oral doses of atorvastatin 80 mg/day and rosuvastatin 40 mg/day over a 6-week period on serum apo B-48 (a marker of intestinal lipoproteins) and remnant lipoprotein cholesterol (RemL-C) levels (a marker of partially metabolized lipoproteins of both intestinal and liver origin), using novel direct assays in 270 hyperlipidemic men and women. Both atorvastatin and rosuvastatin caused significant (p<0.0001) and similar median decreases in TG (-33.0%, -27.6%), RemL-C (-58.7%, -61.5%), and apoB-48 (-37.5%, -32.1%) as compared to baseline. Our findings utilizing a specific immunoassay and a fairly large number of subjects extend prior studies indicating that statins significantly lower apolipoprotein B containing lipoproteins of both intestinal and liver origin.
authors.affiliation: Cardiovascular Research Laboratory, Friedman School of Nutrition Science and Policy at Tufts University and Tufts University School of Medicine, Boston, MA 02111, USA.
authors.forename: Seiko
authors.initials: S
authors.lastname: Otokozawa
authors.forename: Masumi
authors.initials: M
authors.lastname: Ai
authors.forename: Thomas
authors.initials: T
authors.lastname: Van Himbergen
authors.forename: Bela F
authors.initials: BF
authors.lastname: Asztalos
authors.forename: Akira
authors.initials: A
authors.lastname: Tanaka
authors.forename: Evan A
authors.initials: EA
authors.lastname: Stein
authors.forename: Peter H
authors.initials: PH
authors.lastname: Jones
authors.forename: Ernst J
authors.initials: EJ
authors.lastname: Schaefer
mesh_terms: D053283:Apolipoprotein B-48 / Q000494:pharmacology*; D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000378:metabolism*; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D008074:Lipoproteins / Q000737:chemistry*; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage*; D014280:Triglycerides / Q000378:metabolism
chemical_list: D053283:Apolipoprotein B-48; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin